Company performance
Add to research
Current Price
as of Jul 11, 2025$1.84
P/E Ratio
N/A
Market Cap
$183.59M
Description
Add to research
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Metrics
Add to research
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSLS
- Price$1.84-2.90%
Trading Information
- Market cap$183.59M
- Float97.89%
- Average Daily Volume (1m)3,654,188
- Average Daily Volume (3m)2,866,171
- EPS-$0.39
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$5.81M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$6.06M
- EV$67.15M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B6.03
- Debt/Equity3.13
Documents
Add to research
SEC Filings
Factset Street Account